The Influence of Gastrectomy on the Change of Bone Metabolism and Bone Density

Sung Joon Kwon, M.D., Joon Soo Hahm, M.D.*, Yun Ju Cho, M.D.*
Youhern Ahn, M.D.*, Dong Ill Shin. M.D.

*Department of Internal Medicine * and Surgery, College of Medicine,
Hanyang University, Seoul, Korea.*

Objectives : *Abnormalities of bone metabolism could be followed in gastrectomized patients as a late complication. Nowadays, many biochemical and radiologic measurements are applied to detect these abnormalities. The aim of our study is to determine the valuable parameter as an appropriate screening test during long-term follow-up periods and define the usefulness of new biochemical markers for bone metabolism by comparing with traditional markers.*

Methods : *Fifteen patients who had undergone partial gastrecomy were chosen randomly and fifteen healthy controls were compared. Then, several biochemical and radiologic tests were measured. We excluded subjects who proved to have other causes of bone metabolism abnormalities. Ten patients and 10 controls were finally selected .*

Results : *Comparing the data with those of a corresponding control group, the lumbar bone density measured by quantitative computed tomography (QCT) was statistically significantly lower in the patient group (p<0.01). The urinary deoxypyridinoline, a biochemical marker for bone resorption, was statistically higher in the patient group (p<0.025). Osteocalcin, Procollagen I C-terminal peptide (PICP) and Type I collagen C-terminal telopeptide (ICTP) were slightly but not significantly higher in the patient group. The serum parathyroid hormone (PTH) and 25-hydroxy vitamin D levels were similar in both groups.*

Conclusion : *We co suggest that urinary deoxypyridinoline and QCT are appropriate parameters as screening tests for the detection of bone metabolism abnormalities in gastrectomised patients during long-term follow-up. Urinary deoxypyridinoline may be a simple and rapid test which could replace cumbersome 24-hour urinary hydroxyproline.*

Key Words : *Gastrectomy ; bone metabolism ; bone density*

INTRODUCTION

The development of metabolic bone disease that followed after gastrectomy has been reported many years ago, but the incidence of bone metabolism changes after gastrectomy has tended to have quite

---

*Address reprint requests to : Joon Soo Hahm, M.D.
Department of Internal Medicine, Hanyang University Hospital, Sung-Dong Post Office, P.O. Box 93, Seoul, 133-600, Korea*

different results according to authors[1-8]. Furthermore, the mechanisms of these metabolic changes were not apparent. Either a vitamin D or a calcium deficiency or, perhaps, even both together, contributes to reduced bone mass[9].

In the past, although numerous measurements have been used for quantitative methods of bone mass and biochemical markers of bone metabolism in patients with gastrectomy, great divergences were reported in the incidences and results of postgastrectomy bone disease [2-8, 13, 14].

Therefore, we tried to determine what appropriate

screening tests during long-term follow-up periods might be valuable for gastrectomized (subtotal gastrectomy) men, comparing with age and a sex-matched control group, and also to define the usefulness of new biochemical markers for bone metabolism by comparing with the old traditional markers.

Materials and Methods

1. Materials

We studied 15 male patients, who had undergone subtotal gastrectomy (with Billroth Ⅱ anastomosis) because of peptic ulcers and gastric cancers without metastasis or local recurrence, by imaging study during follow-up periods. The patients were referred to our hospital outpatient department for a routine examination after informed consent. Fifteen healthy males with a similar age distribution served as a control group. All participants in the study had their history investigated, physical examination and 12-panel blood chemistry, including liver and renal function tests, after 12-hour fasting periods.

We excluded participants who had any other endocrine, malignant or metabolic bone disease or who had received any medication well known to influence bone metabolism or had abnormal liver or renal functions. Finally, 10 patients and 10 controls participated in our study. All participants had a normal nutritional status, lived at home, had work and led normal life styles, including average physical activity and sexual activity. Also, no one had a history of fracture in the past or present.

2. X-ray & Bone Chemistry

Plain lumber AP and lateral X-ray films were taken. The bone mineral density (BMD) of the lumber spine was measured by quantitative computed tomography (QCT) with the single energy technique (80 kVp) using Gadolinium enhanced computed tomography (GECT) 9800 highlights (software Imagix, University of California, San Francisco, U.S.A.).

3. Biochemical markers for bone metabolism

Serum Procollagen I C-terminal propeptide (PICP) and Type I collagen C-terminal telopeptide (ICTP) levels were determined using a commercially available radioimmunoassay (RIA) kit (^{125}I-labelled, Orion Diagnostica, Finland). The levels of intact parathyroid hormone (PTH) and osteocalcin were determined by a commercially available RIA kit (^{125}I-labelled, Nichols, U.S.A.). The levels of 25-hydroxy vitamin D were determined by a RIA kit (^{3}H-labelled, Nichols, U.S.A.). The spot urinary deoxypyridinoline (DPD) excretion was measured by a ELISA (Metra biosystems, U.S.A.) without limitation of diet.

4. Blood chemistry

Blood chemistry parameters, including liver and renal function tests, calcium, phosphorus and alkaline phosphatase were measured with routine laboratory technique (Hitachi 747 automatic analyzer).

5. Statistical analysis

The Student's t-test was used for statistical evaluation. The data in the text and table are given as the mean± standard deviation (SD).

RESULTS

1. Subjects

The age of patients and controls were 49.3 ± 9.2 years old and 49.7 ± 7.7 years old respectively. The interval since the operation (subtotal gastrectomy) was 113 ± 23.7 months (78 151 months). The height was 168.4 ± 6.13 cm in the patient groups and 168.5 ± 6.79 cm in the control group. The weight of the two groups was 61.0 ± 9.07 kg and 68.7 ± 7.06 kg, respectively. The weight of the patient group was significantly lower than that of the control group ($p<0.025$). The body mass index (BMI) of patients and controls was 21.56 ± 3.44 kg/m^2 and 24.18 ± 1.92 kg/m^2 (Table 1).

Table 1. Comparison of age, height, weight and BMI*

	Patient (n=10)	Control (n=10)
Age (year)	49. ± 9.2	49.7 ± 7.7
Height (cm)	168.4 ± 6.13	168.5 ± 6.79
Weight (kg)	61.0 ± 9.07**	68.7 ± 7.06
BMI (Kg/m2)	21.56 ± 3.44***	24.18 ± 1.92

*: Body mass index **: p-value < 0.0025 ***: p-value < 0.05

Table 2. Biochemical data in gastrectomized patients

	Patient (n=10)		Control (n=10)		Normal value		
Calcium(mg/dl)	8.78	± 0.319	9.1	± 0.386	8.5	-	11.0
Phosphorus(mg/dl)	3.12	± 0.35	3.06	± 0.46	2.5	-	4.8
Alkaline phosphates(KA-u)	5.4	± 1.6	4.4	± 1.2	3.0	-	10.0
Intact PTH(pg/ml)	20.26	± 7.86	18.10	± 7.97	10.0	-	65.0
25-hydroxyvitamin D(nm/dl)	32.74	± 12.25	29.56	± 10.9	25.7	-	15.8
Oseteocalcin(ng/ml)	4.17	± 1.25	3.40	± 0.78	2.3	-	13.8
PICP(ug/1)	128.72	± 61.19	118.85	± 29.7	38.0	-	202.0
ICTP(ug/1)	3.99	± 1.68	3.24	± 0.82	1.8	-	5.0
DPD(nM DPD/mM creatnine)	6.83	± 3.19*	4.45	± 1.2	2.5	-	5.0
BMD(mg/cm3 K2HPO4)	107.81	± 19.25**	131.27	± 20.44	Age matched		

* : p-value < 0.025   ** : p-value < 0.01

2. X-ray and Bone density measurement

There was no evidence of radiologic signs of osteopenia. Vertebral bone density measured by QCT was 107.81 ± 19.25 mg/cm^3 K$_2$HPO$_4$ in patients and 131.27 ± 20.44 mg/cm^3 K$_2$HPO$_4$ in controls. The BMD of gastrectomized patients was significantly lower than that of the controls (p<0.01) (Table 2)(Figure. 1).


Fig. 1. Bone mineral density in patients and controls. Horizontal bar ; mean values.

3. Blood chemistry and Biochemical parameters of bone metabolism

No difference was found in the serum calcium and alkaline phosphatase levels between the groups (Table 2). The spot urinary DPD excretion were 6.83 ± 3.19 nM DPD/mM creatinine in patients and 4.45 ± 1.2 nM DPD/mM creatinine in controls. There was statistically significant increase in the patient group (p<0.025)(Figure. 2). The serum osteocalcin and PICP levels were slightly but not significantly higher in the patient group (Figure. 3, 4). The serum PTH and 25-hydroxy vitamin D levels were similar in both groups. There was no statistical difference in the serum ICTP levels in both groups although serum ICTP levels in patients were higher than in controls (Figure. 5).


Fig. 2. Urinary DPD in patients and controls. Horizontal bar ; mean values

DISCUSSION

Metabolic bone diseases have long been associated with gastric surgery. The incidence of metabolic bone disease after gastrectomy has been estimated about 1-42% even though there was great discrepancy between authors[1-8]. A reduced bone mass has been reported as occurring 5 or more years after gastrectomy[7]. In our study, the average interval since operation was 113 ± 23.7 months. Osteomalacia is most commonly reported, but osteoporosis or combination of oseteomalacia and osteoporosis, and less

Fig. 3. Serum Osteocalcin levels in patients and controls Horizontal bar ; mean values.


**Fig. 4.** Serum PICP levels in patients and controls. Horizontal bar ; mean values

Fig. 5. Serum ICTP levels in patients and controls. Horizontal bar ; mean values.

well-characterized forms of osteopenia, have been described[1,7,8].

In fact, the pathogenesis of osteoporosis has not been explained as satisfactorily as that of oseteomalacia[7]. Osteoporosis is a generalized bone disorder, characterized by a decrease in the quantity of

bone but no change in quality. It occurs most frequently in postmenopausal women and the aged. Osteomalacia is a failure of the organic matrix to mineralize normally. Therefore, osteoporosis was thought to be present if there were radiological abnormalities only, particularly if it was confined to the axial skeleton. If a biochemical disturbance existed, osteomalacia was diagnosed. In certain cases, these diagnoses were supported by bone biopsy.

Although the etiology of postgastrectomy bone disease remains unclear, either a vitamin D or a calcium deficiency or, perhaps, even both together, contribute to a reduced bone mass[9]. Proposed causes of a vitamin D or a calcium deficiency have included malabsorption of vitamin D or calcium[7], a decreased intake of vitamin D or calcium[11], inadequate contact between nutrients and their absorptive sites (either because of altered anatomy or rapid transit)[23] and reduced exposure to sunlight[23]. In our study, all participants had a normal nutritional status, lived at home, had work and led normal life styles, including average physical activity and sexual activity. On the basis of the above facts, it is difficult to assume that either reduced exposure to sunlight or a decreased intake of vitamin D or calcium contributed to a vitamin D or a calcium deficiency. Also no patient has complained of steatorrhea or indigestion or other gastrointestinal symptoms to suggest malabsorption syndrome clinically. Therefore, the loss of gastric acid secretion necessary for solubilization of dietary calcium or the by-pass of the critical absorption surface of the duodenum could be responsible[12].

An apparent relationship between bone mass and body weight indicates that a poor nutritional state contributes to the condition[24,25]. In our study, weight and BMI in the patient group are significantly lower than those of the control (Table 1). According to Korean statistics[26], BMI in the normal weight group ranges from 20 to 25 and lean group is definded when BMI is less than 20. We compared 4 patients whose BMI are less than 20 with patients whose BMI are above 20. We could not find any difference in blood chemistries and biochemical parameters of bone metabolism. Furthermore, bone densitometry using QCT did not reveal any difference between the two groups. Therefore, lean body weight in 4 out of 10 patients did not influence low bone density in the patient group.

Biochemical parameters of bone metabolism were divided into bone formation (osteoblastic activity) and

bone resorption (osteoclastic activity) markers. The serum alkaline phosphatase has been a sensitive marker for bone formation in the past. Serum calcium and phosphorus values seldom lead to detection of postoperative bone disease or indicate specific types of osseous lesion[27]. However, serum alkaline phosphatase levels, reasonably good as screening tests for osteomalacic bone disease, reported as being elevated in 10 to 30% of affected persons and are a more reliable index to postgastrectomy bone disease[27]. In our study, whereas serum calcium was slightly lower in the patient group, phosphorus, alkaline phosphatase, intact PTH and 25-hydroxy vitamin D were slightly higher than the control. However, there was no statistical significance between the two groups in terms of mean serum calcium, phosphorus, alkaline phosphatase, intact PTH and 25-hydroxy vitamin D.

It is difficult to state whether vitamin D deficiency in our study contributed to osteopenia because 25-hydroxy vitamin D is higher in the patient group. Slightly high PTH in the patient group could be a compensation for low calcium. Therefore, we can speculate that reduced bone mass in the patient group could be attributed to a combination of osteoporosis, induced by slightly increased PTH overactivity in compensation for relative calcium deficiency, and osteomalacia on the basis of slightly elevated alkaline phosphatase.

In recent times, new markers for bone metabolism introduced. The serum levels of osteocalcin bone-specific protein have become a most sensitive and specific test for osteoblastic activity[5]. Type I collagen accounts for about 90% of the organic matrix of mineralized bone. The synthetic rate of type I procollagen can be assessed by measuring the serum concentration of its carboxy terminal propeptide, PICP. The serum PICP levels reflect the synthesis of type I collagen and osteoblastic activities[5,15]. In our study, serum osteocalcin levels were slightly increased in the patients, but there was no statistical difference (Figure. 3). Serum PICP levels, in general, tended to be increased in gastrectomized patients[5,15]. Our patients also had slightly increased PICP levels than the controls but there were not statistically significant (Figure. 4). Recently developed serum ICTP, which is a carboxy terminal telopeptide of type I collagen, cross-linked via pyridinoline cross-links and liberated during the degradation of type I collagen and serum ICTP level, which reflects the activity of bone resorption may be of

use in the diagnosis and follow-up of the metabolic status of the bone, especially in states associated with increased lysis of the bone (such as multiple myeloma, osteolytic metastasis, rheumatoid arthritis, immobilization and osteoporosis)[17].

The 24-hour urinary hydroxyproline excretion in the fasting state was widely used as a marker of bone resorption till now[5,7]. The hydroxypyridinium derivatives pyridinoline (PYD) and deoxypyridinoline (DPD) are trifunctional crosslinks found exclusively in mature fibrillar collagens of skeletal tissues. Urinary DPD is considered to be derived from only skeletal collagens. In contrast to hydroxyproline as a conventional bone resorption marker, the pyridinium crosslinks are released during the breakdown of mature collagen and, therefore, are excreted without interference from newly synthesized or intermediate products. Furthermore, urinary concentration appears not to be influenced by the effects of diet or physical exercise. Therefore, pyridinium crosslinks have also been used as a marker of bone resorption[18-20]. In our study, urinary DPD excretion and serum ICTP were measured. Although the ICTP level was slightly higher in the patient group, there was no statistical significance (Figure. 4). However, urinary DPD excretions of gastrectomized patients were significantly more increased than those of controls ($p < 0.025$)(Figure. 1).

Roentgenologic differentiation of osteomalacia from osteoporosis in a patient without pseudofractures may be impossible. It is an accepted concept that at least 30-50% of the bone must be demineralized before detection is possible[28]. No patient in our study showed osteopenia by plain lumbar X-ray AP and lateral view. Therefore, detection of osteopenia needs bone densitometry. The fact that the degree of osteopenia tends to increase with the length of time after surgery points to the need for long-term surveillance[14].

Noninvasive methods measuring bone mass are radiologic photodensitometry, single or dual photon absorptiometry, QCT and dual energy X-ray absorptiometry (DEXA). Invasive method is a bone biopsy in the iliac crest[21,22]. There are two kinds of QCT, i.e. single energy QCT and dual energy QCT. Dual energy QCT may measure most accurately bone mineralization, because vertebral trabecular bone measurements are summed with adjacent calcium deposits in the cortical bone, osteophytes, compression fracture and other factors. The X-ray source used in DEXA has several advantages over the isotope source used in DPA, which

has led to discontinuation of DPA in favor of DEXA in recent years. DEXA has better image resolution and a faster scanning speed[29]. DEXA and dual energy QCT were not available in our institution during this study. In our study, we used single energy (80kVp) QCT with the addition of a mineral calibration phantom (K_2HPO_4). Using this technique, the bone mineral density of gastrectomy patients was significantly lower than that of controls ($p<0.01$)(Figure. 1).

In conclusion, markers for bone metabolism and bone densitometry are necessary in order to detect metabolic bone diseases after gastrectomy, because routine biochemical chemistry and routine lumbar spine X-ray failed to detect these diseases. Therefore, we suggest that urinary DPD and bone densitometry like QCT are appropriate parameters for screening tests for the detection of bone metabolism abnormalities in the gastrectomized patient during a long-term follow-up period especially after 5 years.

Urinary DPD is, specially, a simple and rapid test which can replace the cumbersome 24-hour urinary hydroxyproline. Also, prophylactic administration of supplemental calcium and/or vitamin D, if indicated with monitoring of serum calcium, 25-hydroxy vitamin D and 24-hour urinary calcium might be reasonable after gastric surgery.

REFERENCES

1. Hall GH, Neale G. *Bone rarefaction after partial gastrectomy. Ann Int Med 1963; 59: 455-463.*
2. Melkstrom D, Rundgren A. *Long-term effects after partial gastrectomy in elderly men-a longitudinal population study of men between 70 and 75 years of age. Scand J. Gastroenterol 1982; 17: 433-439.*
3. Aukee S, Alhava EM, Karjalainen P. *Bone Mineral after partial gastrectomy II. Scand J Gastroenterol 1975; 10: 165-169.*
4. Paterson CR, Woods CG, Pulvertaft CN, Fourman P. *Search for osteomalacia in 1228 patients after gastrectomy and other operations on the stomach. Lancet 1965; 27: 1085-1088.*
5. Resch H, Pietschmann P, Pernecker B, Krexner E, Willvonseder R. *The influence of partial gastrectomy on biochemical parameters of bone metabolism and bone density. Clin Investig 1992; 70: 426-429.*
6. Blichert-Toft M, Beck A, Christiansen C, Transbol I. *Effects of gastric resection and vagotomy on blood and bone mineral content. World J Surg 1979; 3: 99-102.*
7. Eddy RL. *Metabolic bone disease after gastrectomy. Am J Med 1971; 50: 442-449.*
8. Garrick R, Ireland AW, Posen S. *Bone abnormalities after gastric surgery; a prospective histological study. Ann Int Med 1971; 75: 221-225.*
9. Nishimura O, Sakamoto H, Furumoto T, Furumptp T, Nosaka K, Kouno K, Hisaki T, Koga S. *Bone disorder in long-term survival after gastrectomy with reference to bone mineral content.. Jpn J Surg 1987; 88: 1684-1694.*
10. Williams JA. *Effects of upper gastro-intestinal surgery on blood formation and bone metabolism. Brit J Surg 1964; 51: 125-135.*
11. Kim CB, Choi SH, Kim YI, Lee YS. *The effects of gastrectomy on calcium balance. J Kor Surgical Society 1994; 46: 472-480.*
12. Filipponi P, Gregorio F, Cristallini S, Mannarelli C, Blass A, Scarponi AM, Vespasiani G. *Partial gastrectomy and mineral metabolism:effect on gastrin-calcitonin release. Bone and Miner 1990; 11: 199-208.*
13. Nilas L, Christiansen C. *Influence of PTH and 1,25(OH)2D on calcium homeostasis and bone mineral content after gastric surgery. Calcif Tissue Int 1985; 37: 461-466.*
14. Klein KB, Orwoll ES, Lieberman DA, Meier DE, McClung MR, Parfitt AM. *Metabolic bone disease in asymptomatic men after partial gastrectomy with Billroth II anastomosis. Gastroenterol 1987; 92: 608-616.*
15. Melkko J, Niemi S, Risteli L, Risteli J. *Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990; 36: 1382-1332.*
16. Thompson GR, Neale G, Watts JM, Booth CC. *Detection of vitamin-D deficiency after partial gastrectomy. Lancet 1966; 19: 623-626.*
17. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. *Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen-a new serum marker of bone collagen degradation. Clin Chem 1993; 39: 635-640.*
18. Seibel MJ, Robins SP, Bilezikian JP. *Urinary pyridinium crosslinks of collagen-specific markers of bone resorption in metabolic bone disease. Trends Endocrinol Metab 1992; 3: 263-270.*
19. Robis SP, Woitage H, Hesley R, Ju J, Seyedin S, Seiebl MJ. *Direct, enzyme-linked immunoassay for urinary pyridinoline as a specific marker for bone resorption. J Bone Miner Res 1994; 9: 1643-1649.*
20. Woitge H, Scheidt-Nave C, Leidig-Bruckner G, Duncan A, Nicol P, Ziegler R, Robins SP. *Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study. J Bone Miner Res 1994; 9: 1433-1440.*
21. Health and public policy committee, American college of physicians; Philadelphia, Pennsylvania. *Radiologic methods to evaluate bone mineral content. Ann Inn Med 1984; 100: 908-911.*

22. Richardson ML, Genant HK, Cann CE, Ettinger B, Gordan GS, Kolb FO, Reiser UJ. *Assessment of metabolic bone diseases by quantitative computed tomography. Clin Orthop 1985; 195: 224-238.*

23. Kaplan MM. *Metabolic bone disease associated with gastrointestinal diseases. Dig Dis Sci 1983; 15: 9-12.*

24. Ott SM, Kilcoyne RF, Chesnut CH. *Longitudinal changes in bone mass after one year as measured by different techniques in patients with osteoporosis. Calcif Tissue Int 1986; 39: 133-138.*

25. Mazess R, Barden Ettinger B, Johnstan et al. *Spine and femur density using dual-photon absorptiometry in US white women. Bone Miner 1987; 2: 211-219.*

26. Lee TH. *Prevalence of obesity in Korean non-insulin dependent diabetic patients. Diabetes Res Clin Pract 1996; 32: 71-80.*

27. Jones C, Williams TA, Nicholson G. *Partial gastrectomy(Stammers FAR, Williams JA, eds), London, Butterworth & Co. Ltd. 1963; P 190.*

28. Garn SM, Poznanski AK, Nagy JM. *Bone measurement in the different diagnosis of osteopenia and osteoporosis. Radiology 1971; 100: 509-518.*

29. Roberto Pacific, Reta Rupich, Michael Griffin, Arkadi Chines, Noah Susman Louis V. *Dual energy radiography versus quantitative computer tomography for the diagnosis of osteoporosis. J of Clinic Endoclinol and Metabol. 1990; 70: 705-709.*